Indian pharma majors to hit US growth bump in FY23
The revenue growth of about 16 leading Indian pharmaceutical companies is estimated to moderate to 6-7% in FY23, says ICRA.
lupin
July 2022
June 2022
May 2022
March 2022
February 2022
January 2022
December 2021
October 2021
March 2021
Sensex, Nifty to slide; Wipro, Vedanta, Tata Power, Lupin, Crompton Greaves shares eyed
The Sensex and Nifty are set to bell the day in negative terrain, tracking weak cues from global peers and similar trends on the SGX Nifty futures.
Sensex, Nifty to open in red; HPCL, ITC, Lupin, IDBI Bank, Dr Reddy’s Lab, Ashok Leyland in focus
The Sensex and Nifty are poised to fall sharply in opening trade on Thursday, in line with Asian peers, as Wall Street suffered its worst sell-off in two years overnight.
Sensex, Nifty to open in red; Future Retail, Vodafone Idea, Lupin, Eveready Ind shares in focus
The BSE Sensex and the NSE Nifty are poised to fall on Friday, following sharp losses across Asia and negative trends on SGX Nifty futures.
Sensex, Nifty to open in red; Nestle, Lupin, Airtel, Indian Oil, Wipro shares in focus
The BSE Sensex and the NSE Nifty are poised to open flat to lower on Friday, following soft cues from global peers and bearish trends on the SGX Nifty.
Soft opening seen for Sensex, Nifty; L&T, Lupin, BHEL, PNB, TVS Motor shares in focus
The BSE Sensex and the NSE Nifty are expected to open flat to lower on Friday, following muted trends on SGX Nifty.
Sensex, Nifty to open lower; HDFC Bank, Maruti, HCL Tech, Lupin, Sun Pharma in focus
The BSE Sensex and the NSE Nifty are poised to start the week on the back foot, tracking mixed global cues and negative trading at SGX Nifty.
Soft opening seen for Sensex, Nifty; RBL Bank, HP Adhesives, RIL, Lupin in focus
The BSE Sensex and the NSE Nifty are slated for a subdued opening on Monday, following mixed cues from Asian peers as Omicron fears grip markets.
Quality issues remain for Indian pharma companies: USFDA
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.
India’s tuberculosis endemic in the Covid-19 era
Like during the pandemic, we must work together to improve awareness and outcomes in diagnosis, prevention, treatment, and eventual elimination of TB from the country.
